M. Fiona Shortt de Hernandez

Great to be learning about the exciting new developments in AI for pharma at the Digital-Tech Pharma & AI conference in London this week!

At #SGOAM26 we are presenting data from the largest trial to date to report results for a HER2-targeted ADC in recurrent HER2-expressing endometrial cancer. Read more: bit.ly/4voJn42 #BioNTech #WomensCancer #GynecologicOncology

📢 JPM 2026|Strategic areas of focus Oncology milestones in 2026: - 7 late-stage data readouts - 6 Phase 3 clinical trial initiations expected - Focus on high-incidence indications, such as lung and breast cancer 📰 bit.ly/3YY5I9L 🎥 bit.ly/3YY5I9L #JPM2026

🔬 At #SABCS25, we shared interim global Phase 2 data from our investigational bispecific antibody program in metastatic #TNBC with our partner @bmsnews Learn more in our press release: bit.ly/48CnnrC #BreastCancerResearch #OncologyScience #BioNTech

Today, together with OncoC4, we announced data on an investigational selective Treg modulator candidate in patients with advanced sqNSCLC. Learn more in our press release: bit.ly/4oGMM9U #LungCancer #NACLC25

FT | IRELAND ARE GOING TO THE PLAY-OFFS!!! YEEEESSSSS!!!!

🇮🇪✌️ A Troy Parrott double sees the Republic of Ireland take down Portugal!

BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”

Global interim Phase 2 data in extensive-stage small cell lung cancer presented at #WCLC25: Investigational approach designed to target PD-L1 and VEGF-A in a single molecule. Full PR: bit.ly/3I1dZVs

Small cell lung cancer is a key focus at #BioNTech with multiple trials across disease stages. At #WCLC25, we share global interim Phase 2 data on our PD-L1xVEGF-A bispecific antibody candidate in extensive-stage small cell lung cancer.

Visited the Parthenon on the Acropolis in Athens yesterday. Simply spectacular 🤩#athens #parthenon #acropolis

Comprehensive Organic Synthesis 3rd Edition is published! Kudos to co-Editor-in-Chief Paul Knochel and all the volume editors and authors that made it possible!

Visiting family in Berlin after working in Halle this week. The beauty of the Brandenburger Tor never fails to amaze me! #Berlin

Incredibly warm in Halle today!!! 37 degrees! 🥵

BioNTech agrees to buy former Covid vaccine rival CureVac for about $1.25 billion in an all-stock deal that will boost its growing oncology business bloomberg.com/news/articles/…

We are partnering with @bmsnews to jointly develop and commercialize our PD-L1xVEGF bispecific #antibody candidate BNT327. Combining our expertise, resources, and global reach, we aim to bring novel combination therapies to patients with #cancer. 🚀 investors.biontech.de/news-releases/…

#VfB #StuttgartLauf2025 #Stuttgart

At #AACR25, we will present data from our #mRNA and immuno-oncology priority programs. These data support execution of our combination strategy in oncology, including first data on the novel combination of our PD-L1xVEGF-A antibody candidate in combination with #ADCs.

BioNTech’s PD-L1xVEGF antibody has shown an impressive rate of one-year survival when used first-line for a serious form of lung cancer. If results stay consistent in larger trials, this approach could become the standard of care. endpts.com/biontech-detai…

⌬⌬⌬Heterocycles 2025⌬⌬⌬ Coming on April 7 (see attached syllabus)! This year will be a reverse classroom format wherein all new material will be discussed with problem solving sessions including real-world consulting questions. Aspiring drug hunters and seasoned veterans: This content is for you. Please review the 2021 lectures on our YouTube channel (bit.ly/3yYyABB) before attending to maximize learning outcomes. Primary textbook available here: books.apple.com/us/book/the-po…. Outside participants are welcome to join over Zoom. As in previous years, those from industry are encouraged to send their problems in advance (after scrubbing IP) for us to solve during class. San Diego locals are welcome to attend in person for free. Please contact this year's TA's Anthony Rodriguez (anrodriguez@scripps.edu) and Philipp Neigenfind (pneigenfind@scripps.edu) for the Zoom link and any other questions you may have.